Charles Finsterwald

Charles Finsterwald began their career in 2005 as an Intern at B. Braun Medical in Switzerland. In 2006, they started working at the University of Lausanne as a Research Assistant, PhD candidate, Scientific Collaborator, and Research Assistant. In 2011, they moved to the Center for Psychiatric Neuroscience, Cery Hospital as a Postdoctoral Research Scientist. In 2012, they joined New York University as a Postdoctoral Research Scientist in Prof. Alberini's laboratory, Center for Neural Science, where they worked on the modulation of stress on the molecular mechanisms underlying long-term memory. In 2014, they became a Senior Scientist at EPFL (École polytechnique fédérale de Lausanne). In 2016, they co-founded GliaPharm SA, where they currently serve as the Chief Scientific Officer. GliaPharm is a Swiss biotech that develops innovative therapeutic strategies for neurodegenerative diseases by targeting glial cells in the brain.

Charles Finsterwald began their educational journey in 2002 when they earned a Bachelor of Science (B.Sc.) in Biology from the University of Lausanne. Charles then continued their studies at the same university, graduating with a Master of Science (M.Sc.) in Medical Biology and Immunology in 2007. Following this, they attended the Lemanic Neuroscience Doctoral School, where they obtained a Doctor of Philosophy (PhD) in Neuroscience in 2011. In 2012, they attended New York University where they completed a Project Management course. In 2014, they attended EPFL (École polytechnique fédérale de Lausanne) for a Venture Challenge.